These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37751011)

  • 1. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
    Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
    Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
    Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
    J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
    [No Abstract]   [Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab: A Review in Advanced Biliary Tract Cancer.
    Fung S; Syed YY
    Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
    Reesink DJ; van Melick HHE; van der Nat PB; Los M; Horenblas S; van de Garde EMW;
    World J Urol; 2023 Jun; 41(6):1551-1562. PubMed ID: 37145158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.
    Tam VC; Ramjeesingh R; Burkes R; Yoshida EM; Doucette S; Lim HJ
    Curr Oncol; 2022 Sep; 29(10):7072-7085. PubMed ID: 36290832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
    Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
    Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
    Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
    JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
    Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
    J Oncol Pharm Pract; 2023 Sep; 29(6):1381-1386. PubMed ID: 36320173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04).
    Shimoyama R; Imamura Y; Uryu K; Mase T; Taguri M; Okuda T; Fujimura Y; Hayashi M; Tanaka S; Sawamukai K; Minami H
    Jpn J Clin Oncol; 2024 Jan; 54(1):70-80. PubMed ID: 37801431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
    Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
    Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
    Rimini M; Fornaro L; Rizzato MD; Antonuzzo L; Rossari F; Satake T; Vandeputte H; Vivaldi C; Pressiani T; Lucchetti J; Kim JW; Abidoye O; Rapposelli IG; Tamberi S; Finkelmeier F; Giordano G; Nichetti F; Chon HJ; Braconi C; Pirrone C; Castet F; Tamburini E; Yoo C; Parisi A; Diana A; Scartozzi M; Prager GW; Avallone A; Schirripa M; Kim IH; Perkhofer L; Oneda E; Verrico M; Adeva J; Chan SL; Spinelli GP; Personeni N; Garajova I; Rodriquenz MG; Leo S; Salani F; De Rosa A; Lavacchi D; Foti S; Ikeda M; Dekervel J; Niger M; Balsano R; Tonini G; Kang M; Bekaii-Saab T; Esposito L; Boccaccino A; Himmelsbach V; Landriscina M; Djaballah SA; Zanuso V; Masi G; Lonardi S; Rimassa L; Casadei-Gardini A
    Eur J Cancer; 2024 Sep; 208():114199. PubMed ID: 39002348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
    Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
    Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.